| HER2-Low Breast Carcinoma studied in …STUDIED_INderived24 of 24show fewer |
|---|
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796880Phase 2 · recruiting Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06298084Phase 1/Phase 2 · recruiting Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533826Phase 2 · recruiting TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383506Phase 1 · recruiting A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06144944Phase 3 · active not recruiting Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07137416Phase 1 · recruiting Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer · condition mapped CURATED_BROADER · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05514717Phase 1 · terminated A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06224673Phase 2 · recruiting ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07198724Phase 1/Phase 2 · recruiting ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07446452Phase 2 · recruiting Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07358182recruiting Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06957886Phase 3 · recruiting A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06210776recruiting A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830382recruiting HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05466786recruiting Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05795101Phase 2 · recruiting TRUDI: TDXD+Durva in HER2+/Low IBC · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06877416recruiting Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06733233Phase 2 · not yet recruiting A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05911958Phase 2 · recruiting A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06433804completed Clinicopathological Parameters of HER2 Low Breast Cancers · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040593completed Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04602117Phase 1 · withdrawn ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer · condition mapped ALIAS · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05754047completed Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients · condition mapped ONTOLOGY_EXACT · 24 trials mapped (19 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |